Compare COGT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | RYTM |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | 2018 | 2017 |
| Metric | COGT | RYTM |
|---|---|---|
| Price | $26.90 | $113.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | $55.82 | ★ $139.76 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,871,000.00 | N/A |
| Revenue This Year | N/A | $74.20 |
| Revenue Next Year | $5,819.52 | $74.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.36 | $74.50 |
| 52 Week High | $43.73 | $122.20 |
| Indicator | COGT | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 36.08 | 57.34 |
| Support Level | N/A | $100.33 |
| Resistance Level | $37.34 | $113.31 |
| Average True Range (ATR) | 1.77 | 8.32 |
| MACD | -0.36 | 0.87 |
| Stochastic Oscillator | 6.38 | 78.21 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.